Publications des scientifiques de l'IRD

Hien H., Meda N., Diagbouga S., Zoure E., Yameogo S., Tamboura H., Some J., Ouiminga A., Rouet F., Drabo A., Hien A., Nicolas J., Chappuy H., Van de Perre P., Msellati Philippe, Nacro B. (2013). 24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children : ANRS 12103/12167. African Health Sciences, 13 (2), p. 287-294. ISSN 1680-6905.

Titre du document
24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children : ANRS 12103/12167
Année de publication
2013
Type de document
Article référencé dans le Web of Science WOS:000325695600014
Auteurs
Hien H., Meda N., Diagbouga S., Zoure E., Yameogo S., Tamboura H., Some J., Ouiminga A., Rouet F., Drabo A., Hien A., Nicolas J., Chappuy H., Van de Perre P., Msellati Philippe, Nacro B.
Source
African Health Sciences, 2013, 13 (2), p. 287-294 ISSN 1680-6905
Background: There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future therapeutic strategies. Objectives: To assess 24-month immuno-virological, adherence, tolerance, and effectiveness of a once-a-day ART with DDI, 3TC and EFV. Methods: A phase 2 open trial including 51 children aged from 30 months to 15 years, monitored a once-a-day regimen for 24 months from 2006 to 2008 in the Departement de Pediatrie du CHUSS, at Bobo-Dioulasso in Burkina Faso. We tested immunological and virological response, adherence, tolerance and resistance of the treatment. Results: Children with CD4 > 25% at 24 months were 67.4% (33/49) CI 95% [54%, 80%]. The proportion of children with viral plasma RNA < 300 cp/ml at 24 months of treatment was 81.6 % (40/49) CI [68.0% 91.2%]. Good adherence was obtained with more than 88% adherence > 95% over the 24 months. Drugs were well tolerated. Conclusions: Given the limited number of antiretroviral drugs available in Africa and the inadequacy of laboratory monitoring in support program, once-a-day treatment and especially the DDI-based combination strategies could be an attractive operational option.
Plan de classement
Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
BURKINA FASO
Localisation
Fonds IRD [F B010061199]
Identifiant IRD
fdi:010061199
 Demander le PDF  DOI
Contact